RETA - レアタ・ファ―マシュ―ティカルズ (Reata Pharmaceuticals Inc.) レアタ・ファ―マシュ―ティカルズ

 RETAのチャート


 RETAの企業情報

symbol RETA
会社名 Reata Pharmaceuticals Inc (レアタ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 レアタ・ファーマスーティカルズ(Reata Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は製品候補の識別・開発・商品化に従事する。製品候補はミトコンドリア機能、酸化ストレス及び炎症生物学に関与する調節タンパク質の活性調節を含み、深刻で生命を脅かす疾患の患者の医療ニーズを満たす。同社の主力製品候補には結合組織疾患(CTD-PAH)に関連する肺動脈高血圧症(PAH)の第III相試験で研究されるバルドキソロンメチル、 フリードライヒ運動失調症、ミトコンドリア・ミオパチー症を含む複数の疾患の治療用フェーズⅡ臨床開発中の肺高血圧症(PH)、フリードライヒ運動失調症、ミトコンドリアミオパチー及び転移性黒色腫を含む疾患の治療用第II相臨床開発のOmaveloxoloneを含む。   レアタ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床ステ―ジで、酸化性ストレスと炎症に関連するタンパク質の活性を調整する薬剤を開発・商業化することに従事する。薬剤候補の「Bardoxoloneメチル」と「Omaveloxolone」は酸化防止剤炎症モジュレ―タからなる。本社はテキサス州ア―ビング。   Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
本社所在地 2801 Gateway Drive Suite 150 Irving TX 75063 USA
代表者氏名 J. Warren Huff J.ウォーレンハフ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 972-865-2206
設立年月日 2002年
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 93人
url www.reatapharma.com
nasdaq_url https://www.nasdaq.com/symbol/reta
adr_tso
EBITDA EBITDA(百万ドル) -50.50300
終値(lastsale) 66.97
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 1803.745
売上高 売上高(百万ドル) 62.48400
企業価値(EV) 企業価値(EV)(百万ドル) 1743.66
当期純利益 当期純利益(百万ドル) -53.11500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Reata Pharmaceuticals Inc revenues increased 56% to $40M. Net loss increased 29% to $24.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 37% to $42.9M (expense) General and administrative - Balancing v increase of 56% to $14.2M (expense).

 RETAのテクニカル分析


 RETAのニュース

   Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%- Is Further Upside Left in the Stock?  2021/07/02 06:16:55 Nasdaq
Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%: Is Further Upside Left in the Stock? Nasdaq
   Movie theater industry has too many screens, former Regal CFO says  2021/06/09 01:36:34 Bitcoin Ethereum News
The post Movie theater industry has too many screens, former Regal CFO says appeared on BitcoinEthereumNews.com . AMC Entertainments revitalization plan hinges on adding new theaters, but former Regal Entertainment CFO David Ownby told Jefferies there are too many screens in North America. Box office experts agree
   AMC Has Too Many Screens: Insiders  2021/06/08 14:47:00 Baystreet Canada
AMC Entertainments (NYSE:AMC) revitalization plan hinges on adding new theaters, but former Regal Entertainment CFO David Ownby told Jefferies there are too many screens in North America. Box office experts agree that moviegoing is not going to disappear. The pastime is inexpensive, enjoyable and can drive billions of dollars in ticket sales. In the last two weeks, the domestic box office has set ticket sales records for the pandemic era, a welcome sign of recovery for the industry. Its a particularly promising signal for AMC, which raised around $2 billion in cash over the last six months and plans to use some of the fresh funds to acquire more theater locations. Its best-case scenario is that the public will continue to turn out to see films on the big screen, and with more market share, AMC will reap the benefits of those ticket sales. As AMC moves to add more theaters, its searching for high-performing locations that were abandoned during the pandemic, it may also need to shed some of its underperforming cinemas.
   Reata Pharmaceuticals Inc - Class A Shares Close the Week 23.2% Higher - Weekly Wrap  2021/05/28 22:30:00 Kwhen Finance
Reata Pharmaceuticals Inc - Class A (RETA) shares closed this week 23.2% higher than it did at the end of last week. The stock is currently up 10.6% year-to-date, down 5.9% over the past 12 months, and up 857.6% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.2%. Trading Activity Shares traded as high as $142.17 and as low as $113.37 this week.Shares closed 3e+1% below its 52-week high and 8e+1% above its 52-week low.Trading volume this week was 5.9% lower than the 10-day average and 14.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -60.8% The company's stock price performance over the past 12 months lags the peer average by -112.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Reata Pharmaceuticals Inc - Class A Shares Close the Week 41.6% Higher - Weekly Wrap  2021/05/21 22:30:00 Kwhen Finance
Reata Pharmaceuticals Inc - Class A (RETA) shares closed this week 41.6% higher than it did at the end of last week. The stock is currently down 10.2% year-to-date, down 30.6% over the past 12 months, and up 749.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $114.59 and as low as $77.23 this week.Trading volume this week was 41.8% lower than the 10-day average and 7.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -136.3% The company's stock price performance over the past 12 months lags the peer average by -172.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Reata Pharmaceuticals Inc - Class A Shares Close the Week 41.6% Higher - Weekly Wrap  2021/05/21 22:30:00 Kwhen Finance
Reata Pharmaceuticals Inc - Class A (RETA) shares closed this week 41.6% higher than it did at the end of last week. The stock is currently down 10.2% year-to-date, down 30.6% over the past 12 months, and up 749.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $114.59 and as low as $77.23 this week.Trading volume this week was 41.8% lower than the 10-day average and 7.3% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -136.3% The company's stock price performance over the past 12 months lags the peer average by -172.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Leerink Partners Stick to Their Buy Rating for Reata Pharmaceuticals By Investing.com  2021/03/04 11:30:00 Investing.com
Leerink Partners Stick to Their Buy Rating for Reata Pharmaceuticals
   Recap: Reata Pharmaceuticals Q4 Earnings  2021/03/01 07:06:00 Benzinga
Shares of Reata Pharmaceuticals (NASDAQ:RETA) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share increased …
   Worldwide Movie Theatres Industry to 2024 - Featuring AMC, Regal Entertainment and Cinemark  2020/12/16 17:00:00 PR Newswire
DUBLIN, Dec. 16, 2020 /PRNewswire/ -- The "Global Movie Theatres Market: Size & Forecasts with Impact Analysis of COVID-19 (2020-2024 Edition)" report has been added to ResearchAndMarkets.com's offering. This report provides an in-depth analysis of the global movie theatres market with…
   DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm  2020/12/09 00:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern District of Texas on behalf of investors that purchased Reata Pharmaceuticals, Inc. (NASDAQ: RETA) securities between October 15, 2019 and August 7, 2020 (the “Class Period”). Investors have until December 14, 2020 to apply to the Court to be appointed as lead plaintiff in
   Deadline on Dec. 14th coming up in Lawsuit for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares  2020/12/07 20:38:56 OpenPR
A deadline is coming up on December 14, 2020 in the lawsuit filed for certain investors of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) over alleged securities laws violations by Reata Pharmaceuticals, Inc. Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 レアタ・ファ―マシュ―ティカルズ RETA Reata Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)